Therapeutic Area

RNA-targeted therapy

Therapeutic area intelligence for RNA-targeted therapy with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 3
Catalysts: 0
Companies: 3

Companies

AstraZeneca →

Ionis Pharmaceuticals →

IONIS PHARMS INC. →

Assets

FDA →

TRYNGOLZA →

Recent signals(3)

RegulatoryJuly 3, 2026

FDA Accepts Supplemental Application for WAINUA Autoinjector by AstraZeneca

The FDA has accepted a supplemental application for the WAINUA autoinjector containing EPLONTERSEN SODIUM.

RegulatoryJune 30, 2026

FDA Accepts Supplemental Application for TRYNGOLZA Autoinjector

The FDA has accepted a supplemental application for the TRYNGOLZA autoinjector, indicating progress in its regulatory pathway.

RegulatoryJune 27, 2026

FDA Grants Priority Review for TRYNGOLZA Autoinjector Submission

The FDA has granted priority review for the supplemental application of TRYNGOLZA (olezarsen sodium) autoinjector by Ionis Pharmaceuticals.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.